DSIP
Delta Sleep Inducing Peptide · Delta Sleep-Inducing Peptide
The sleep peptide your brain makes naturally. Restores deep sleep architecture without next-day grogginess.
What is DSIP?
DSIP was first isolated from rabbit brain tissue in 1977 by a Swiss research group who noticed it could induce delta-wave sleep (the deepest, most restorative sleep stage) when injected into recipient animals. Since then, it has been extensively studied — over 100 papers — as a potential treatment for insomnia and disrupted sleep architecture.
What makes DSIP interesting compared to sleeping pills is its mechanism. It does not sedate you or knock you out. Instead, it appears to normalise your sleep architecture — increasing the proportion of time spent in deep, slow-wave sleep where physical recovery and growth hormone release occur. People do not report feeling drugged; they report waking up feeling actually rested.
The biohacking community uses DSIP primarily for two purposes: improving deep sleep quality (especially for people who track sleep with devices like WHOOP or Oura and see poor deep sleep scores), and resetting disrupted circadian rhythms after travel or shift work.
How Does It Work?
DSIP modulates sleep by interacting with multiple neurotransmitter systems rather than simply activating GABA (like benzodiazepines). It influences serotonin, dopamine, and endorphin systems, and appears to modulate CRH (corticotropin-releasing hormone) — reducing the stress axis activity that prevents deep sleep.
It also has documented effects on LH (luteinising hormone) release and can modulate pain perception through endorphin pathways. The multi-system action explains why it normalises sleep rather than simply inducing sedation — it is resetting the systems that regulate natural sleep, not overriding them.
What Does The Research Say?
Moderate evidence. Some human data, mostly animal studies.
Over 100 published papers since 1977. Human studies show improved sleep quality scores, increased deep sleep percentage, and normalisation of disrupted sleep patterns. Studies in chronic insomnia patients showed significant improvement without tolerance development.
Research also shows interesting secondary benefits: stress resilience, normalisation of blood pressure in hypertensive patients, and potential anti-opioid withdrawal effects. However, many studies are older (1980s-1990s), methodology varies, and large modern RCTs are lacking. DSIP has proven frustratingly difficult to develop commercially due to its short half-life in blood.
Reported Dosages
These are dosages reported in research literature and community reports. They are NOT medical recommendations. Always consult a healthcare professional.
Research studies typically used 25-100 mcg/kg IV or IM.
Community protocols: 100-300 mcg subcutaneously, 30-60 minutes before bed.
Some use nightly for 1-2 weeks then cycle off.
Others use intermittently for jet lag or acute sleep disruption.
These are research dosages, not medical recommendations.
Side Effects & Risks
Generally well-tolerated in clinical studies. Occasional drowsiness (expected), mild headache, and rarely a paradoxical alerting effect at higher doses. No reported tolerance, dependence, or withdrawal — which distinguishes it fundamentally from conventional sleep medications.
Legal Status by Country
Not approved. Available as research chemical.
Not FDA-approved. Research chemical. Not scheduled.
Not approved. Research chemical.
Not approved. Research chemical.
Important Disclaimer
This profile is for educational and research purposes only. It does not constitute medical advice. DSIP may be regulated or illegal in your jurisdiction. Do not use any compound without consulting a qualified healthcare professional. StackPedia does not sell, supply, or promote the use of any controlled substance.